Seaport Therapeutics, Inc. Common Stock (SPTX)

• Market cap: $917M
• 1 day: -8.77%
• 5 days: -13.81%
• 1 month: -8.77%
• 3 months: -8.77%
• 6 months: -8.77%
• Year to date: -8.77%
• 1 year: -8.77%
• 5 years: -8.77%
• 10 years: -8.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.